Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery

Abstract

Purpose. To evaluate the effectiveness and optical quality of 3.0% topical diquafosol versus 0.05% cyclosporine A in dry eye patients following cataract surgery. Methods. In total, 40 eyes of 40 patients newly diagnosed with dry eye syndrome 1 week after cataract surgery were randomized to receive either 3.0% diquafosol ophthalmic solution six times daily or 0.05% cyclosporine A twice daily for 3 months. Outcome measures were tear film break-up time (TBUT), results on Schirmer 1 test, ocular surface staining score, the ocular surface disease index (OSDI) score, and higher-order aberrations (HOAs). Measurements were taken at baseline and at 1, 2, and 3 months. Results. In the diquafosol group, TBUT showed higher outcomes than the cyclosporine A group at 1 and 3 months. Both groups showed increased scores on Schirmer 1 test. The ocular surface staining score decreased in all periods in both groups. Vertical coma and total HOAs decreased more in the cyclosporine A group than in the diquafosol group at 3 months. Conclusion. Both 3.0% diquafosol and 0.05% cyclosporine A were effective in treating dry eye after cataract surgery. Diquafosol was more effective in increasing the tear secretion, but cyclosporine A was more effective in improving optical aberrations.

Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study

“…In late years, there have been some reports that examined an effect of DQS for dry eye after cataract surgery. The application of DQS improves signs including higher order aberrations and symptoms in dry eye patients after cataract surgery 21,22,43–45. Higher-order aberrations were not investigated in this study, but they may be improved because tear film stability was improved to prolong BUT in the diquafosol treatment group.…”

The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye

“…Cataract surgery has been reported in the literature to induce dry eye and to exacerbate pre-existing dry eye. 1 , 2 , 5 , 8 – 14 Treatments for postoperative dry eye have been extensively reported in the literature and include nonsteroidal antiinflammatory drugs, topical corticosteroids, artificial tears, topical cyclosporine 0.05%, lifitegrast, 3.0% diquafosol, 1% carboxymethylcellulose sodium, oral lactoferrin, oral doxycycline, punctal plugs, and autologous serum, among others. 3 , 8 , 10 , 15 – 24 Yet, little has been reported in the literature on the preoperative incidence of dry eye in a cataract population.…”

A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers

“…Both DQS and RBM are mucin secretogogues; thus, they are expected to be effective for the treatment of DES in office workers. Since it became available in Japan in 2011, DQS ophthalmic solution has been used and proven effective for treating various types of DES, including aqueous-deficient, short TBUT-type DES and postoperative DES following cataract or laser in situ keratomileusis 34 , 36 , 45 – 49 . Due to its unique properties for mucous tissue protection, RBM has been widely used for the treatment of gastric and duodenal ulcers.…”